share_log

Axon Enterprise (NASDAQ:AXON) PT Lowered to $134.00

Axon Enterprise (NASDAQ:AXON) PT Lowered to $134.00

AXON企業(納斯達克:AXON)PT降至134.00美元
Defense World ·  2022/07/14 21:22

Axon Enterprise (NASDAQ:AXON – Get Rating) had its price target lowered by equities researchers at Credit Suisse Group from $169.00 to $134.00 in a research note issued to investors on Thursday, The Fly reports. Credit Suisse Group's target price suggests a potential upside of 44.76% from the company's current price.

據The Fly報道,在週四發佈給投資者的一份研究報告中,瑞士信貸集團的股票研究人員將Axon Enterprise(納斯達克:AXON-GET評級)的目標價從169.00美元下調至134.00美元。瑞士信貸集團的目標價暗示,該公司目前的股價有44.76%的潛在上行空間。

AXON has been the topic of several other research reports. StockNews.com raised Axon Enterprise from a "hold" rating to a "buy" rating in a research note on Saturday, June 18th. Morgan Stanley downgraded Axon Enterprise from an "overweight" rating to an "equal weight" rating and set a $120.00 target price on the stock. in a research note on Monday, May 23rd. Robert W. Baird cut their target price on Axon Enterprise from $145.00 to $125.00 in a research note on Wednesday, May 11th. Northland Securities cut their target price on Axon Enterprise from $180.00 to $130.00 in a research note on Thursday, May 12th. Finally, JMP Securities reissued a "buy" rating and issued a $195.00 price objective on shares of Axon Enterprise in a research note on Wednesday, June 1st. One investment analyst has rated the stock with a hold rating, eight have assigned a buy rating and one has assigned a strong buy rating to the company's stock. According to MarketBeat.com, Axon Enterprise presently has an average rating of "Buy" and an average target price of $169.00.

軸突一直是其他幾份研究報告的主題。在6月18日星期六的一份研究報告中,StockNews.com將Axon Enterprise的評級從持有上調至買入。摩根士丹利將Axon Enterprise的評級從“增持”下調至“持平”,併為該股設定120.00美元的目標價.在5月23日星期一的一份研究報告中。5月11日,羅伯特·W·貝爾德在一份研究報告中將Axon Enterprise的目標價從145.00美元下調至125.00美元。Northland Securities在5月12日星期四的一份研究報告中將Axon Enterprise的目標價從180.00美元下調至130.00美元。最後,JMP證券在6月1日星期三的一份研究報告中重新發布了“買入”評級,並對Axon Enterprise的股票發佈了195.00美元的目標價。一名投資分析師對該股的評級為持有,八名分析師給出了買入評級,一名分析師給出了該公司股票的強力買入評級。根據MarketBeat.com的數據,Axon Enterprise目前的平均評級為買入,平均目標價為169.00美元。

Get
到達
Axon Enterprise
Axon企業
alerts:
警報:

Shares of AXON opened at $92.57 on Thursday. The firm has a market cap of $6.57 billion, a price-to-earnings ratio of 178.02 and a beta of 0.61. The stock has a 50 day moving average of $94.73 and a 200-day moving average of $116.90. The company has a current ratio of 2.43, a quick ratio of 2.18 and a debt-to-equity ratio of 0.02. Axon Enterprise has a 52 week low of $82.49 and a 52 week high of $209.00.

Axon股價週四開盤報92.57美元。該公司市值為65.7億美元,市盈率為178.02倍,貝塔係數為0.61%。該股的50日移動均線切入位在94.73美元,200日移動均線切入位在116.90美元。該公司的流動比率為2.43,速動比率為2.18,債務權益比率為0.02。Axon Enterprise的52周低點為82.49美元,52周高點為209.00美元。

Axon Enterprise (NASDAQ:AXON – Get Rating) last issued its earnings results on Tuesday, May 10th. The biotechnology company reported $0.76 EPS for the quarter. Axon Enterprise had a return on equity of 3.90% and a net margin of 4.62%. The company had revenue of $256.43 million during the quarter, compared to analyst estimates of $233.57 million. During the same quarter last year, the firm earned ($0.75) EPS. The business's revenue was up 31.5% on a year-over-year basis. On average, sell-side analysts predict that Axon Enterprise will post 1.35 earnings per share for the current fiscal year.
Axon Enterprise(納斯達克:Axon-Get Rating)最近一次發佈財報是在5月10日(星期二)。這家生物技術公司公佈本季度每股收益為0.76美元。Axon Enterprise的股本回報率為3.90%,淨利潤率為4.62%。該公司本季度營收為2.5643億美元,而分析師預期為2.3357億美元。去年同期,該公司每股收益為0.75美元。該業務的收入同比增長了31.5%。賣方分析師平均預測,Axon Enterprise本財年每股收益將達到1.35美元。

In other news, Director Mark W. Kroll sold 3,159 shares of the company's stock in a transaction that occurred on Wednesday, June 8th. The stock was sold at an average price of $102.82, for a total value of $324,808.38. Following the sale, the director now directly owns 13,691 shares in the company, valued at approximately $1,407,708.62. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Corporate insiders own 6.90% of the company's stock.

在其他新聞方面,董事馬克·克羅爾在6月8日(星期三)的一筆交易中出售了3159股該公司股票。這隻股票的平均售價為102.82美元,總價值為324,808.38美元。交易完成後,董事現在直接擁有該公司13,691股股份,價值約1,407,708.62美元。這筆交易是在提交給美國證券交易委員會的一份文件中披露的,該文件可以在美國證券交易委員會網站上看到。公司內部人士持有該公司6.90%的股份。

Hedge funds have recently added to or reduced their stakes in the company. BerganKDV Wealth Management LLC grew its position in Axon Enterprise by 50.2% during the 2nd quarter. BerganKDV Wealth Management LLC now owns 2,554 shares of the biotechnology company's stock worth $238,000 after acquiring an additional 854 shares during the last quarter. Private Advisor Group LLC grew its position in Axon Enterprise by 6.0% during the 2nd quarter. Private Advisor Group LLC now owns 3,665 shares of the biotechnology company's stock worth $341,000 after acquiring an additional 207 shares during the last quarter. Handelsinvest Investeringsforvaltning grew its position in Axon Enterprise by 9.6% during the 2nd quarter. Handelsinvest Investeringsforvaltning now owns 54,800 shares of the biotechnology company's stock worth $5,106,000 after acquiring an additional 4,800 shares during the last quarter. State of Alaska Department of Revenue grew its position in Axon Enterprise by 5.8% during the 2nd quarter. State of Alaska Department of Revenue now owns 10,191 shares of the biotechnology company's stock worth $949,000 after acquiring an additional 555 shares during the last quarter. Finally, Moody National Bank Trust Division bought a new stake in Axon Enterprise during the 2nd quarter worth approximately $1,351,000. Institutional investors own 72.06% of the company's stock.

對衝基金最近增持或減持了該公司的股份。BerganKDV Wealth Management LLC在第二季度將其在Axon Enterprise的頭寸增加了50.2%。BerganKDV Wealth Management LLC現在擁有2554股這家生物技術公司的股票,價值23.8萬美元,在上個季度額外購買了854股。私人顧問集團LLC在第二季度將其在Axon Enterprise的頭寸增加了6.0%。Private Advisor Group LLC現在持有這家生物技術公司3,665股股票,價值341,000美元,在上個季度又購買了207股。HandelsInvest Invester for Valtning在第二季度將其在Axon Enterprise的頭寸增加了9.6%。HandelsInvest InvestingsFor Valtning現在擁有54,800股這家生物技術公司的股票,價值5,106,000美元,在上個季度又購買了4,800股。阿拉斯加州税務局在第二季度將其在Axon Enterprise的頭寸增加了5.8%。阿拉斯加州税務局在上個季度增持了555股後,現在持有10,191股這家生物技術公司的股票,價值94.9萬美元。最後,穆迪國家銀行信託部門在第二季度購買了Axon Enterprise價值約1,351,000美元的新股份。機構投資者持有該公司72.06%的股份。

Axon Enterprise Company Profile (Get Rating)

Axon企業公司簡介(獲取評級)

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, TASER, and Software and Sensors. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.

Axon Enterprise,Inc.在美國和國際上以泰瑟品牌開發、製造和銷售導電能源設備(CED)。它通過兩個部分運作,泰瑟槍和軟件和傳感器。該公司還提供硬件和基於雲的軟件解決方案,使執法部門能夠捕獲、安全存儲、管理、共享和分析視頻和其他數字證據。

Read More

閲讀更多內容

  • Get a free copy of the StockNews.com research report on Axon Enterprise (AXON)
  • 3 More Stocks For the Second Half to Consider
  • United Natural Foods Stock is Ready to be Snacked On
  • Elastic Stock is a Buoyant Search Play
  • 3M (NYSE: MMM) Is Now A Good Time To Buy 3M After Downgrades?
  • Apple's Global Smartphone Market Share Increases by 20%, Should You Consider The Stock?
  • 免費獲取StockNews.com關於Axon Enterprise(Axon)的研究報告
  • 下半年將再考慮3只股票
  • 聯合天然食品庫存準備好被點心
  • 彈性股票是一種活躍的搜索業務
  • 3M(紐約證券交易所代碼:MMM)評級下調後,現在是買入3M的好時機嗎?
  • 蘋果全球智能手機市場份額增長20%,你應該考慮股票嗎?

Receive News & Ratings for Axon Enterprise Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axon Enterprise and related companies with MarketBeat.com's FREE daily email newsletter.

接受Axon企業日報的新聞和評級-在下面輸入您的電子郵件地址,通過MarketBeat.com的免費每日電子郵件時事通訊接收Axon Enterprise和相關公司的最新新聞和分析師評級的每日簡明摘要。

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論